# The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

> **NCT00449813** · PHASE4 · TERMINATED · sponsor: **Takeda** · enrollment: 40 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease
- Non-erosive Reflux Disease

## Interventions

- **DRUG:** Pantoprazole

## Key facts

- **NCT ID:** NCT00449813
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2007-10
- **Final completion:** 2008-11
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Inclusion-rate does not seem feasible anymore to obtain te required number of patients before the end of the trial.
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00449813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00449813, "The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00449813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*